
    
      This is a mutlicenter, randomized, double-blind, parallell-group study. Subejcts who meet the
      eligibility criteria at screening and meet the randomization criteria at the end of a 4 week
      run-in period will enter a 12 week treatment period. There will be a 7 day follow-up period
      after the treatment period.
    
  